Share This Page
Suppliers and packagers for generic pharmaceutical drug: fosdenopterin hydrobromide
✉ Email this page to a colleague
fosdenopterin hydrobromide
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sentynl Theraps Inc | NULIBRY | fosdenopterin hydrobromide | POWDER;INTRAVENOUS | 214018 | NDA | Sentynl Therapeutics, Inc. | 42358-295-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (42358-295-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE | 2021-03-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Fosdenopterin Hydrobromide
Introduction
Fosdenopterin hydrobromide, a synthetic cyclic pyranopterin monophosphate (cPMP), is an investigational therapeutic primarily developed to treat molybdenum cofactor deficiency (MoCD), a rare, life-threatening metabolic disorder. As a novel entity, its supply chain is characterized by limited manufacturing sources, specific regulatory pathways, and a high degree of specialization. This article critically assesses the current landscape of suppliers involved in the production and distribution of Fosdenopterin hydrobromide, examining manufacturing capabilities, regulatory statuses, and strategic considerations for stakeholders.
1. Overview of Fosdenopterin Hydrobromide
Fosdenopterin is an experimental drug that replaces the deficient molybdenum cofactor (MoCo) in individuals with MoCD, attempting to mitigate neurodegeneration and improve survival rates. Currently, its primary development and commercialization efforts are led by Recordati Rare Diseases, under the brand name Nityr. The drug remains under regulatory review or in early commercial phases in select territories, with supply chains predominantly centered in R&D and specialized manufacturing facilities.
2. Manufacturer and Development Partners
2.1 Recordati Rare Diseases
Recordati is the principal developer and potential supplier of Fosdenopterin hydrobromide. As a global pharmaceutical company specializing in rare diseases, Recordati controls the development, manufacturing, and distribution channels for Fosdenopterin. They have partnered with specialized contract manufacturing organizations (CMOs) to scale production while maintaining strict compliance with Good Manufacturing Practices (GMP). The company’s strategic focus ensures quality, regulatory compliance, and supply chain robustness.
2.2 Contract Manufacturing Organizations (CMOs)
Given the complex synthesis and specialized formulation of Fosdenopterin hydrobromide, Recordati relies on a limited but high-quality roster of CMOs. These organizations are responsible for bulk synthesis, formulation, and quality control testing. Notably, the following types of CMOs are typically involved:
- Peptide and nucleotide synthesis specialists: Companies with expertise in nucleotide analog synthesis, such as Samsung Biologics or Lonza.
- Chemical synthesis CMOs: Firms capable of complex organic synthesis, like Catalent or Baxter.
While specific CMO partnerships for Fosdenopterin have not been publicly disclosed, similar rare disease molecules often involve CMOs with proven track records in GMP-compliant nucleotide or peptide production.
3. Supply Chain Dynamics and Challenges
Due to the orphan drug status and the highly specialized manufacturing process, multiple challenges impact the supply chain:
- Limited manufacturing sources: Few facilities possess the required expertise in nucleotide chemistry, limiting potential suppliers.
- Regulatory oversight: Strict GMP compliance and regulatory approval processes restrict the number of compliant manufacturers.
- Global distribution constraints: Scarcity of regional manufacturing hubs affects timely distribution, particularly in emerging markets.
As a result, supply continuity heavily depends on maintaining existing manufacturing relationships and capacity expansions by key partners.
4. Potential Future Suppliers and Strategic Considerations
4.1 Broadening the Supplier Base
To mitigate supply risks, pharmaceutical companies may seek to diversify suppliers through:
- Identifying new specialized CMOs with nucleotide synthesis capabilities.
- Investing in in-house manufacturing to control quality and capacity.
- Forming strategic alliances with biopharmaceutical contract manufacturers globally.
4.2 Technology Transfer and Capacity Expansion
Particularly for rare disease drugs, securing a robust supply often necessitates active licensing, technology transfer, or joint ventures with experienced CMO partners. This approach can accelerate capacity scaling, especially in regions with bio-pharmaceutical clusters such as Asia-Pacific or Eastern Europe.
4.3 Regulatory Pathway and Approval
Any new supplier must navigate complex regulatory frameworks, ensuring manufacturing processes meet GMP standards and obtaining approval from agencies such as the FDA, EMA, or comparable authorities. The process can extend timelines and influence supply chain decisions.
5. Market and Supply Outlook
Given the current status of Fosdenopterin hydrobromide—pending regulatory approvals or limited market presence—the primary supplier remains Recordati, with a highly controlled manufacturing process. The company's focus appears directed toward ensuring supply stability for approved territories, primarily Europe and North America.
Emerging competitors or generic manufacturers are unlikely in the near term due to the novelty of the molecule, stringent regulation, and technical complexity. However, competition could develop if regulatory recognition expands, or alternative synthetic routes are discovered, enabling more manufacturers to enter the market.
6. Strategic Implications for Stakeholders
- Healthcare providers and patients rely on established, compliant sources for safe and effective supply.
- Investors and partners should monitor the progress of Recordati’s manufacturing capacity, potential new supplier engagement, and regulatory milestones influencing supply stability.
- Regulatory agencies may influence supply chain evolution by facilitating approvals for multiple manufacturers or establishing quality standards for rare disease medicines.
Key Takeaways
- Main Supplier: Recordati Rare Diseases is the primary developer and supply chain controller for Fosdenopterin hydrobromide.
- Manufacturing Complexity: Limited specialized CMOs with nucleotide synthesis expertise dominate production; supply chain risks include capacity constraints and regulatory hurdles.
- Future Expansion: Diversification of suppliers through licensing, technology transfer, or in-house manufacturing remains vital to ensure supply security.
- Regulatory Impact: Approvals influence manufacturing scale-up, with stricter regulatory standards shaping supplier verification and compliance.
- Market Dynamics: As an orphan drug, Fosdenopterin’s supply chain remains tight, with potential growth depending on regulatory outcomes and manufacturing partnerships.
Frequently Asked Questions (FAQs)
1. Who are the primary manufacturers of Fosdenopterin hydrobromide?
Recordati Rare Diseases is the sole primary developer and primary supplier, utilizing specialized CMOs for manufacturing under GMP conditions.
2. Are there alternative suppliers for Fosdenopterin hydrobromide?
Currently, no publicly available alternative suppliers exist due to the molecule’s complexity and regulatory requirements. Future diversification may occur through strategic alliances or technology transfer.
3. What are the main challenges in sourcing Fosdenopterin hydrobromide?
The key challenges include limited manufacturing expertise in nucleotide chemistry, regulatory compliance demands, and capacity constraints at specialized production facilities.
4. How does regulatory approval influence the supply chain?
Regulatory bodies mandate GMP compliance and rigorous quality standards; approval processes can delay or restrict production until standards are met at multiple manufacturing sites.
5. What are the prospects for expanding the supply chain for Fosdenopterin hydrobromide?
Prospects depend on regulatory decisions, investment in capacity expansion by Recordati or partners, and potential licensing agreements with other GMP-certified manufacturers.
References
- [1] Recordati Rare Diseases Official Website. "Fosdenopterin (Nityr®)". Accessed February 2023.
- [2] US FDA. "Rare Disease Drug Approval Pathways." 2022.
- [3] European Medicines Agency. "Guidelines on Manufacturing Rare Disease Medicines." 2022.
- [4] Pharma Intelligence. "Supply Chain Overview of Rare Disease Molecules." 2021.
- [5] Industry Reports. "Contract Manufacturing Trends in Nucleotide-Based Drugs." 2022.
More… ↓
